STELLA PHARMA CORPORATION Logo

STELLA PHARMA CORPORATION

Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.

4888 | T

Overview

Corporate Details

ISIN(s):
JP3399680002
LEI:
Country:
Japan
Address:
大阪市中央区高麗橋三丁目2番7号 ORIX高麗橋ビル
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stella Pharma Corporation is a pharmaceutical company engaged in the research, development, manufacturing, and sales of innovative drugs. The company specializes in Boron Neutron Capture Therapy (BNCT), a targeted radiation treatment for cancer. Its primary focus is on the development of boron compounds, including its approved drug Steboronine®, which is administered to patients prior to neutron irradiation. This therapy is primarily used for treating unresectable, locally advanced, or recurrent head and neck cancer. Stella Pharma aims to contribute to global healthcare by advancing BNCT as a new standard of care for various types of cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 05:26
Registration Form
確認書
Japanese 8.2 KB
2025-11-14 05:25
Interim Report
半期報告書-第19期(2025/04/01-2026/03/31)
Japanese 202.7 KB
2025-06-26 07:06
Registration Form
確認書
Japanese 8.1 KB
2025-06-26 07:05
Annual Report
有価証券報告書-第18期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-06-26 07:05
Governance Information
内部統制報告書-第18期(2024/04/01-2025/03/31)
Japanese 21.7 KB
2025-06-25 06:52
Post-Annual General Meeting Information
臨時報告書
Japanese 21.4 KB
2024-11-12 05:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-12 05:06
Interim Report
半期報告書-第18期(2024/04/01-2025/03/31)
Japanese 192.3 KB
2024-07-01 02:34
Post-Annual General Meeting Information
臨時報告書
Japanese 28.0 KB
2024-06-28 07:05
Governance Information
内部統制報告書-第17期(2023/04/01-2024/03/31)
Japanese 21.3 KB
2024-06-28 07:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-28 07:04
Annual Report
有価証券報告書-第17期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-02-14 05:13
Quarterly Report
四半期報告書-第17期第3四半期(2023/10/01-2023/12/31)
Japanese 145.0 KB
2024-02-14 05:13
Report Publication Announcement
確認書
Japanese 8.1 KB
2023-11-14 06:08
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all STELLA PHARMA CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for STELLA PHARMA CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for STELLA PHARMA CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tango Therapeutics, Inc. Logo
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America
TNGX
Tarsus Pharmaceuticals, Inc. Logo
Develops novel therapies for eye care, including the first FDA-approved Demodex blepharitis drug.
United States of America
TARS
TAUNS Laboratories, Inc. Logo
Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.
Japan
197A
Taysha Gene Therapies, Inc. Logo
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
United States of America
TSHA
Tchaikapharma High Quality Medicines AD Logo
Develops and makes affordable generic drugs for cardiovascular & metabolic diseases.
Bulgaria
THQM
TDSPHARM Co., Ltd. Logo
Develops and manufactures transdermal drug delivery systems like patches, plasters, and OTC products.
South Korea
464280
Tectonic Therapeutic, Inc. Logo
Developing biologic therapies that modulate GPCRs for diseases with unmet needs.
United States of America
TECX
Tego Science, Inc. Logo
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
South Korea
191420
Develops radiopharmaceuticals that use targeted radiation to image and treat various cancers.
United States of America
TLX
Telomir Pharmaceuticals, Inc. Logo
Developing an oral small molecule to reverse aging and treat age-related diseases.
United States of America
TELO

Talk to a Data Expert

Have a question? We'll get back to you promptly.